The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer

FEBS Journal

Volumn 280, Issue 9, 2013, Pages 2105-2116

  Hart, Martin ^a   Wach, Sven ^b   Nolte, Elke ^b   Szczyrba, Jaroslaw ^a   Menon, Roopika ^c   Taubert, Helge ^b   Hartmann, Arndt ^b   Stoehr, Robert ^b   Wieland, Wolf ^d   Grässer, Friedrich A ^a   Wullich, Bernd ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

gene expression; gene regulation, post transcriptional; non coding RNA; oncogene

Indexed keywords

ISOPROTEIN; MESSENGER RNA; MICRORNA 145; TRANSCRIPTION FACTOR ERG;

3' UNTRANSLATED REGION; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TARGETING; GENE TRANSLOCATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN RNA BINDING; PROTO ONCOGENE; PROTO ONCOGENE ERG; RNA SEQUENCE; RNA SPLICING; TISSUE SECTION;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RNA INTERFERENCE; RNA, MESSENGER; TRANS-ACTIVATORS; UP-REGULATION;

EID: 84876918822     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12236     Document Type: Article

References (42)

1. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, &, Visakorpi T, (2007) MicroRNA expression profiling in prostate cancer. Cancer Res 67, 6130-6135. (Pubitemid 47037493)
2. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, et al,. (2008) Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68, 6162-6170.
3. Ozen M, Creighton CJ, Ozdemir M, &, Ittmann M, (2008) Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27, 1788-1793. (Pubitemid 351380263)
4. Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, Senzer N, Eklund AC, Han J, &, Nemunaitis J, (2009) MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 16, 206-216.
5. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G, &, Jung K, (2009) Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126, 1166-1176.
6. Szczyrba J, Loprich E, Wach S, Jung V, Unteregger G, Barth S, Grobholz R, Wieland W, Stohr R, Hartmann A, et al,. (2010) The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res 8, 529-538.
7. Meister G, (2007) miRNAs get an early start on translational silencing. Cell 131, 25-28. (Pubitemid 47498539)
8. Sachdeva M, &, Mo YY, (2010) MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 70, 378-387.
9. Xiao F, Zuo Z, Cai G, Kang S, Gao X, &, Li T, (2009) miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res 37, D105-D110.
10. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, et al,. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648. (Pubitemid 41528150)
11. Scheble VJ, Braun M, Beroukhim R, Mermel CH, Ruiz C, Wilbertz T, Stiedl AC, Petersen K, Reischl M, Kuefer R, et al,. (2010) ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 23, 1061-1067.
12. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K, &, Mo YY, (2009) p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 106, 3207-3212.
13. Wang L, Tang H, Thayanithy V, Subramanian S, Oberg AL, Cunningham JM, Cerhan JR, Steer CJ, &, Thibodeau SN, (2009) Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res 69, 9490-9497.
14. Zaman MS, Chen Y, Deng G, Shahryari V, Suh SO, Saini S, Majid S, Liu J, Khatri G, Tanaka Y, et al,. (2010) The functional significance of microRNA-145 in prostate cancer. Br J Cancer 103, 256-264.
15. Peng X, Guo W, Liu T, Wang X, Tu X, Xiong D, Chen S, Lai Y, Du H, Chen G, et al,. (2011) Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One 6, e20341.
16. Spizzo R, Nicoloso MS, Croce CM, &, Calin GA, (2009) SnapShot: microRNAs in cancer. Cell 137, 586-586.e1.
17. Chen X, Gong J, Zeng H, Chen N, Huang R, Huang Y, Nie L, Xu M, Xia J, Zhao F, et al,. (2010) MicroRNA145 targets BNIP3 and suppresses prostate cancer progression. Cancer Res 70, 2728-2738.
18. Kiriakidou M, Nelson PT, Kouranov A, Fitziev P, Bouyioukos C, Mourelatos Z, &, Hatzigeorgiou A, (2004) A combined computational-experimental approach predicts human microRNA targets. Genes Dev 18, 1165-1178. (Pubitemid 38669037)
19. Seth A, &, Watson DK, (2005) ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 41, 2462-2478. (Pubitemid 41540623)
20. Hart AH, Corrick CM, Tymms MJ, Hertzog PJ, &, Kola I, (1995) Human ERG is a proto-oncogene with mitogenic and transforming activity. Oncogene 10, 1423-1430.
21. Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R, Suleman K, Varambally S, Brenner JC, MacDonald T, et al,. (2010) Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 12, 590-598.
22. Mani RS, Iyer MK, Cao Q, Brenner JC, Wang L, Ghosh A, Cao X, Lonigro RJ, Tomlins SA, Varambally S, et al,. (2011) TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers. Cancer Res 71, 5387-5392.
23. Toubaji A, Albadine R, Meeker AK, Isaacs WB, Lotan T, Haffner MC, Chaux A, Epstein JI, Han M, Walsh PC, et al,. (2011) Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. Mod Pathol 24, 1511-1520.
24. Esquela-Kerscher A, &, Slack FJ, (2006) Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6, 259-269.
25. Salek-Ardakani S, Smooha G, de Boer J, Sebire NJ, Morrow M, Rainis L, Lee S, Williams O, Izraeli S, &, Brady HJ, (2009) ERG is a megakaryocytic oncogene. Cancer Res 69, 4665-4673.
26. Wang J, Cai Y, Yu W, Ren C, Spencer DM, &, Ittmann M, (2008) Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res 68, 8516-8524.
27. Rajan P, Elliott DJ, Robson CN, &, Leung HY, (2009) Alternative splicing and biological heterogeneity in prostate cancer. Nat Rev Urol 6, 454-460.
28. Szczyrba J, Nolte E, Hart M, Doll C, Wach S, Taubert H, Keck B, Kremmer E, Stohr R, Hartmann A, et al,. (2013) Identification of ZNF217, hnRNP-K, VEGF-A and IPO7 as targets for microRNAs that are downregulated in prostate carcinoma. Int J Cancer 132, 775-784.
29. Shnyreva M, Schullery DS, Suzuki H, Higaki Y, &, Bomsztyk K, (2000) Interaction of two multifunctional proteins. Heterogeneous nuclear ribonucleoprotein K and Y-box-binding protein. J Biol Chem 275, 15498-15503. (Pubitemid 30337282)
30. Matlin AJ, Clark F, &, Smith CW, (2005) Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol 6, 386-398. (Pubitemid 40637856)
31. Zhang J, Guo H, Zhang H, Wang H, Qian G, Fan X, Hoffman AR, Hu JF, &, Ge S, (2011) Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene. Cancer 117, 86-95.
32. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, &, Murphy GP, (1983) LNCaP model of human prostatic carcinoma. Cancer Res 43, 1809-1818. (Pubitemid 13122588)
33. Stone KR, Mickey DD, Wunderli H, Mickey GH, &, Paulson DF, (1978) Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21, 274-281. (Pubitemid 8283045)
34. Korenchuk S, Lehr JE, MClean L, Lee YG, Whitney S, Vessella R, Lin DL, &, Pienta KJ, (2001) VCaP, a cell-based model system of human prostate cancer. In Vivo 15, 163-168. (Pubitemid 32328191)
35. Pfuhl T, Mamiani A, Durr M, Welter S, Stieber J, Ankara J, Liss M, Dobner T, Schmitt A, Falkai P, et al,. (2008) The LARK/RBM4a protein is highly expressed in cerebellum as compared to cerebrum. Neurosci Lett 444, 11-15.
36. Motsch N, Pfuhl T, Mrazek J, Barth S, &, Grasser FA, (2007) Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) induces the expression of the cellular microRNA miR-146a. RNA Biol 4, 131-137. (Pubitemid 351237914)
37. Gross H, Hennard C, Masouris I, Cassel C, Barth S, Stober-Grasser U, Mamiani A, Moritz B, Ostareck D, Ostareck-Lederer A, et al,. (2012) Binding of the heterogeneous ribonucleoprotein K (hnRNP K) to the Epstein-Barr virus nuclear antigen 2 (EBNA2) enhances viral LMP2A expression. PLoS One 7, e42106.
38. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al,. (2005) Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33, e179.
39. Schaefer A, Jung M, Miller K, Lein M, Kristiansen G, Erbersdobler A, &, Jung K, (2010) Suitable reference genes for relative quantification of miRNA expression in prostate cancer. Exp Mol Med 42, 749-758.
40. T method. Nat Protoc 3, 1101-1108. (Pubitemid 351818697)
41. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, et al,. (2006) TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66, 8337-8341. (Pubitemid 44449140)
42. Szczyrba J, Nolte E, Wach S, Kremmer E, Stohr R, Hartmann A, Wieland W, Wullich B, &, Grasser FA, (2011) Downregulation of Sec23A protein by miRNA-375 in prostate carcinoma. Mol Cancer Res 9, 791-800.